Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia

Siyi Hu1, Liangwei Li, Jingjuan Qiao

  • 1Laboratory of Molecular and Cellular Immunology, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027, PR China.

Insights

Optimizing the anti-ErbB2 single-chain antibody (scFv) gene sequence for Pichia pastoris expression significantly boosted production yields. This enhanced scFv shows promise for ErbB2-targeted cancer immunotherapy.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Immunology

Background:

  • Anti-ErbB2 antibodies are crucial for studying ErbB2 functions and treating ErbB2-overexpressing tumors.
  • Initial expression of an anti-ErbB2 single-chain antibody (scFv) in Pichia pastoris yielded low amounts (1-2 mg/L).

Purpose of the Study:

  • To enhance the production yield of an anti-ErbB2 scFv in Pichia pastoris.
  • To investigate codon optimization and culture conditions for improved scFv expression.

Main Methods:

  • Synthesized a full-length scFv gene using Pichia pastoris preferred codons.
  • Optimized culture conditions including pH, casamino acids, and methanol induction time.
  • Purified the secreted scFv using Ni2+ chelating affinity chromatography.

Main Results:

  • Codon optimization increased scFv expression 3- to 5-fold, reaching 6-10 mg/L.
  • Northern blotting confirmed enhanced translation efficiency as the primary driver of increased expression.
  • Maximal expression was achieved at pH 6.5-7.0 with 2% casamino acids after 72h methanol induction.
  • A high-purity scFv product (>95%) was obtained with a final yield of 10-15 mg/L.
  • Functional studies demonstrated efficient internalization of the scFv into ErbB2-overexpressing cells.

Conclusions:

  • Codon optimization is an effective strategy to improve recombinant protein production in Pichia pastoris.
  • The optimized anti-ErbB2 scFv is readily produced, purified, and shows potential for ErbB2-targeted immunotherapy.